Microcurrent stimulation & macular degeneration

December 19, 2015

Microcurrent stimulation in the treatment of dry and wet macular degeneration

Purpose: To determine the safety and efficacy of the application of transcutaneous (transpalpebral) microcurrent stimulation to slow progression of dry and wet macular degeneration or improve vision in dry and wet macular degeneration.

Results: Significant increases were seen in VA in Dry AMD (P=0.012, Wilcoxon one-sample test), but in Wet AMD, improvements did not reach statistical significance (P=0.059). In Dry AMD eyes, twice as many patients showed increase in VA (52%) compared to those showing deterioration (26%), with improvements being often sizeable, whereas deteriorations were usually very slight. In WAMD eyes, five of six (83%) patients showed an increase and none showed deterioration.
Conclusion: The substantial changes observed over this period, combined with continued improvement for patients who continued treatment once a month, are encouraging for future studies. The changes observed indicate the potential efficacy of microcurrent to delay degeneration and possibly improve age-related macular degeneration, both wet and dry. However, this study has no control arm, so results should be treated with caution. Randomized double-blind controlled studies are needed to determine long-term effects.

For more info:

https://www.dovepress.com/microcurrent-stimulation-in-the-treatment-of-dry-and-wet-macular-degen-peer-reviewed-article-OPTH

 


iPhone6 Plus and KNFB Reader

December 19, 2015

The following article is by Lauren Tappan.

     “As a low-vision user of digital equipment, I am always looking to
up-grade what I presently use.   I am looking for a phone/ I-Pad system
that will allow me to take a picture of text and then read it to me.  Hopefully, the screen will be large enough to make the icons and text more visible.
    There are a few pieces of digital equipment out there that seem on the
edge of possibly performing these tasks.  Both the Grand Pad and the
Jitterbug have targeted the “elderly” market for their products.  Unfortunately, they both miss the mark when it comes to serving the visually limited population.  The Jitterbug’s Touch 3 screen is still way to small and it does not read text.  You might be able to download the KNFB REader app but I am not sure how well it will work on this phone.
   The Grand Pad has a larger screen but it is a closed system and still does not allow a download of the KNFB Reader app which allow the user to read text.  Both of these companies have said that they have new products lines looming in the future.  Hopefully, they will take all of this into consideration.
     Meantime, I have looked at Version’s I-Phone 6 Plus.  The screen if larger and I am not trying to see if it is possible to download the KNFB reader on this phone.
     Look up I-Phone 6 Plus on YouTube.  The KNFB seems to like this phone and they have a U-Tube to demonstrate it.
Lauren

New Heart-Failure drug can cause Macular Degeneration

December 13, 2015

Novartis has produced a new drug named ENTRESTO. It is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure  and reduced ejection fraction.  They list all the preliminary side effects.

After its release they found it can cause macular degeneration and Altzheimer disease.

If you already have  the preliminary factors for macular  degeneration, such as hereditaty predisposition, smoking, over-65, poor diet, slow adjustment to darkness, etc., discuss with your doctor if he prescribes Entresto.

For more info:

http://www.philly.com/philly/blogs/healthcare/Temple-Wills-Eye-docs-new-heart-failure-drug-could-theoretically-increase-risk-of-Alzheimers.html

http://www.news-medical.net/news/20151210/New-heart-failure-drug-may-increase-patients-risk-of-Alzheimers-disease-macular-degeneration.aspx